ATE469174T1 - Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung - Google Patents
Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendungInfo
- Publication number
- ATE469174T1 ATE469174T1 AT05815961T AT05815961T ATE469174T1 AT E469174 T1 ATE469174 T1 AT E469174T1 AT 05815961 T AT05815961 T AT 05815961T AT 05815961 T AT05815961 T AT 05815961T AT E469174 T1 ATE469174 T1 AT E469174T1
- Authority
- AT
- Austria
- Prior art keywords
- peptides
- shaped
- amphipathic helix
- amphipathic
- disclosed
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 208000011616 HELIX syndrome Diseases 0.000 title 1
- 101150092476 ABCA1 gene Proteins 0.000 abstract 2
- 102000055510 ATP Binding Cassette Transporter 1 Human genes 0.000 abstract 2
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 230000001258 dyslipidemic effect Effects 0.000 abstract 1
- 231100000065 noncytotoxic Toxicity 0.000 abstract 1
- 230000002020 noncytotoxic effect Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61939204P | 2004-10-15 | 2004-10-15 | |
| PCT/US2005/036933 WO2006044596A2 (en) | 2004-10-15 | 2005-10-14 | Multi-domain amphipathic helical peptides and methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE469174T1 true ATE469174T1 (de) | 2010-06-15 |
Family
ID=36203530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05815961T ATE469174T1 (de) | 2004-10-15 | 2005-10-14 | Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US7572771B1 (de) |
| EP (2) | EP2218736A1 (de) |
| JP (1) | JP5091679B2 (de) |
| AT (1) | ATE469174T1 (de) |
| AU (1) | AU2005295640B2 (de) |
| CA (1) | CA2584048C (de) |
| DE (1) | DE602005021534D1 (de) |
| ES (1) | ES2346771T3 (de) |
| WO (1) | WO2006044596A2 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080227686A1 (en) * | 2006-06-16 | 2008-09-18 | Lipid Sciences, Inc. | Novel Peptides that Promote Lipid Efflux |
| WO2008039843A2 (en) * | 2006-09-26 | 2008-04-03 | Lipid Sciences, Inc. | Novel peptides that promote lipid efflux |
| US20110059549A1 (en) | 2007-05-09 | 2011-03-10 | Coleman Matthew A | Methods and systems for producing nanolipoprotein particles |
| WO2009129263A1 (en) * | 2008-04-15 | 2009-10-22 | The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. | Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase |
| WO2010020822A1 (en) * | 2008-08-19 | 2010-02-25 | University Of Patras | Therapy for apolipoprotein-induced hypertriglyceridemia |
| WO2011066511A1 (en) | 2009-11-30 | 2011-06-03 | The U.S.A., As Represented By The Secretary Department Of Health And Human Services | Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof |
| CA2834349A1 (en) * | 2011-04-26 | 2012-11-01 | Molecular Express, Inc. | Liposomal formulations |
| CA2834657A1 (en) | 2011-04-29 | 2012-11-01 | Kinemed, Inc. | Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents |
| US9644038B2 (en) | 2011-12-21 | 2017-05-09 | The Regents Of The University Of California | Apolipoprotein nanodiscs with telodendrimer |
| JP2015525799A (ja) * | 2012-08-10 | 2015-09-07 | ユニバーシティ・オブ・ノース・テキサス・ヘルス・サイエンス・センターＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｎｏｒｔｈ Ｔｅｘａｓ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅ Ｃｅｎｔｅｒ | ターゲティングポリアミノ酸および脂肪酸のコンジュゲートを含む薬物送達ビークル |
| EP2885408B1 (de) | 2012-08-16 | 2023-01-25 | Synthetic Genomics, Inc. | Digital-zu-biologisch-wandler |
| WO2015057583A1 (en) | 2013-10-14 | 2015-04-23 | The United States Of America, As Represented By The Secretary | Treatment of chronic kidney disease with sahps |
| WO2015173633A2 (en) | 2014-05-02 | 2015-11-19 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| WO2016019333A1 (en) | 2014-07-31 | 2016-02-04 | Kinemed, Inc. | The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties |
| WO2016049061A1 (en) | 2014-09-22 | 2016-03-31 | Lawrence Livermore National Security, Llc | Electrochemical flow-cell for hydrogen production and nicotinamide co-factor dependent target reduction, and related methods and systems |
| US11529390B2 (en) * | 2015-03-19 | 2022-12-20 | Institut De Cardiologie De Montreal | PCSK9 inhibitory polypolypeptides and methods of use |
| US12226529B2 (en) | 2015-08-25 | 2025-02-18 | Lawrence Livermore National Security, Llc | Stable nanolipoprotein particles and related compositions methods and systems |
| WO2017044899A1 (en) * | 2015-09-11 | 2017-03-16 | Lawrence Livermore National Security, Llc | Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation |
| EP3490579B1 (de) | 2016-07-27 | 2025-09-10 | Hartis-Pharma SA | Kombinationstherapie zur behandlung von sichelzellanämie und wiederherstellung von rbc-funktionen |
| US11207422B2 (en) | 2017-05-02 | 2021-12-28 | Lawrence Livermore National Security, Llc | MOMP telonanoparticles, and related compositions, methods and systems |
| WO2018204495A1 (en) | 2017-05-02 | 2018-11-08 | Synthetic Genomics, Inc. | Nanolipoprotein particles and related compositions methods and systems for loading rna |
| US20200102356A1 (en) * | 2018-10-01 | 2020-04-02 | NMC Inc. | Compositions and Methods for the Treatment of Huanglongbing (HLB) aka Citrus Greening in Citrus Plants |
| US20240366521A1 (en) * | 2023-01-17 | 2024-11-07 | Qana Therapeutics Inc. | Nanoparticles and methods of use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4643988A (en) | 1984-05-15 | 1987-02-17 | Research Corporation | Amphipathic peptides |
| DE3436928A1 (de) * | 1984-10-09 | 1986-04-10 | Siegel, Rolf, Dr., 8700 Würzburg | Alloplastische gefaessprothese, verfahren zu deren herstellung |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| ATE171192T1 (de) | 1992-06-12 | 1998-10-15 | Innogenetics Nv | Peptide und proteine, verfahren zur ihren herstellung und die verwendung als cholesterol- annehmer |
| US6156727A (en) | 1996-09-05 | 2000-12-05 | Uab Research Foundation | Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US7205280B2 (en) | 1998-03-11 | 2007-04-17 | Cognosci, Inc. | Methods of suppressing microglial activation |
| US7354894B2 (en) | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| AU4976101A (en) | 2000-03-31 | 2001-10-15 | Univ California | Control of a gene induced by oxidized lipids in human artery wall cells |
| US7166578B2 (en) | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US6469007B2 (en) * | 2000-11-28 | 2002-10-22 | Wyeth | Serotonergic agents |
| US6930085B2 (en) * | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
| US7947645B2 (en) | 2004-09-02 | 2011-05-24 | Cognosci, Inc. | APO E analogs and methods for their use |
| GB0420970D0 (en) | 2004-09-21 | 2004-10-20 | Smithkline Beecham Corp | Novel triazoloquinoline compounds |
| US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
| US8710429B2 (en) | 2007-12-21 | 2014-04-29 | The Board Of Regents Of The University Of Ok | Identification of biomarkers in biological samples and methods of using same |
-
2005
- 2005-10-14 AT AT05815961T patent/ATE469174T1/de not_active IP Right Cessation
- 2005-10-14 US US11/577,259 patent/US7572771B1/en not_active Expired - Lifetime
- 2005-10-14 WO PCT/US2005/036933 patent/WO2006044596A2/en not_active Ceased
- 2005-10-14 JP JP2007536912A patent/JP5091679B2/ja not_active Expired - Lifetime
- 2005-10-14 EP EP10004512A patent/EP2218736A1/de not_active Withdrawn
- 2005-10-14 CA CA2584048A patent/CA2584048C/en not_active Expired - Lifetime
- 2005-10-14 ES ES05815961T patent/ES2346771T3/es not_active Expired - Lifetime
- 2005-10-14 AU AU2005295640A patent/AU2005295640B2/en not_active Expired
- 2005-10-14 EP EP05815961A patent/EP1812474B1/de not_active Expired - Lifetime
- 2005-10-14 DE DE602005021534T patent/DE602005021534D1/de not_active Expired - Lifetime
-
2009
- 2009-07-02 US US12/497,443 patent/US8071746B2/en not_active Expired - Lifetime
-
2010
- 2010-04-23 US US12/766,761 patent/US8148323B2/en not_active Expired - Lifetime
-
2012
- 2012-02-28 US US13/407,132 patent/US8835378B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US8148323B2 (en) | 2012-04-03 |
| CA2584048C (en) | 2016-08-09 |
| US8835378B2 (en) | 2014-09-16 |
| EP1812474A2 (de) | 2007-08-01 |
| AU2005295640A1 (en) | 2006-04-27 |
| US8071746B2 (en) | 2011-12-06 |
| WO2006044596A3 (en) | 2006-09-08 |
| CA2584048A1 (en) | 2006-04-27 |
| US20120148642A1 (en) | 2012-06-14 |
| WO2006044596A2 (en) | 2006-04-27 |
| US7572771B1 (en) | 2009-08-11 |
| JP5091679B2 (ja) | 2012-12-05 |
| US20100203099A1 (en) | 2010-08-12 |
| EP1812474B1 (de) | 2010-05-26 |
| JP2008516605A (ja) | 2008-05-22 |
| WO2006044596A8 (en) | 2006-06-29 |
| AU2005295640B2 (en) | 2011-07-28 |
| ES2346771T3 (es) | 2010-10-20 |
| AU2005295640A2 (en) | 2006-04-27 |
| DE602005021534D1 (de) | 2010-07-08 |
| US20090270331A1 (en) | 2009-10-29 |
| EP2218736A1 (de) | 2010-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE469174T1 (de) | Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung | |
| Chuhma et al. | Dopamine neuron glutamate cotransmission evokes a delayed excitation in lateral dorsal striatal cholinergic interneurons | |
| Kaliszewska et al. | Experience-dependent plasticity of the barrel cortex in mice observed with 2-DG brain mapping and c-Fos: effects of MMP-9 KO | |
| DE602004022424D1 (de) | Proteasominhibitoren und verfahren zu deren anwendung | |
| ATE517638T1 (de) | Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln | |
| EP1779220A4 (de) | System und verfahren zum anordnen von haptischen effekten | |
| DE602006012513D1 (de) | Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin | |
| WO2003089457A3 (en) | Peptide inhibitors of protein kinase c ϝ for pain management | |
| DE602005007373D1 (de) | IDENTIFIKATION UND VERWENDUNG VON miRNAs ZUR DIFFERENZIERUNG MYELOGENER LEUKÄMIEZELLEN | |
| DE602005008970D1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten | |
| DE602004020263D1 (de) | Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen | |
| CY1119238T1 (el) | Αλας ηλεκτρικου οξεος του 1-[2-(2-χλωρο-4-{[(r)-2-υδροξυ-2-(8-υδροξυ-2-οξο-1,2-διϋδροκινολιν-5-υλ)αιθυλαμινο]μεθυλ]}-5-μεθοξυφαινυκαρβαμοϋλ)αιθυλ]πιπεριδιν-4-υλ εστερα διφαινυλ-2-υλκαρβαμικου οξεος και χρηση αυτου για την θεραπεια πνευμονικων διαταραχων | |
| DE60133472D1 (de) | Verfahren und vorrichtung zur herstellung von elektrodenplatten für zellen und diese elektrodenplatten verwendende zelle | |
| EA200801942A1 (ru) | Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон | |
| WO2001082917A3 (en) | Treatment of hypertriglyceridemia and other conditions using lxr modulators | |
| DE602004017283D1 (de) | Verfahren zur behandlung von schwerer herzinsuffizienz und medikament dafür | |
| ATE497763T1 (de) | Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen | |
| DE602005026866D1 (de) | Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen | |
| TR199902192T2 (xx) | Anti-CDL40 bile�iklerinin tedavi ama�l� uygulama y�ntemleri | |
| DE602005000485D1 (de) | Nukleinsäurenachweisverfahren mittels mehreren Paaren von Donorflurophoren und Quenchemolekülen in derselben Sonde | |
| EP1499190A4 (de) | Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b | |
| ATE398921T1 (de) | Modulare anordnung und verfahren zum züchten von wassertieren | |
| DE69433243D1 (de) | Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit | |
| BR0313588A (pt) | Métodos para o tratamento da demência com base em apo e genótipo | |
| DE60124780D1 (de) | Vorrichtung und verfahren zur serienvermehrung von säugerzellen zum animpfen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |